- Home
- DBL vs OLMA Comparison
DBL vs OLMA Comparison
Compare DBL & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBL
- OLMA
- Stock Information
- Founded
- DBL 2011
- OLMA 2006
- Country
- DBL United States
- OLMA United States
- Employees
- DBL N/A
- OLMA N/A
- Industry
- DBL
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- DBL
- OLMA Health Care
- Exchange
- DBL Nasdaq
- OLMA Nasdaq
- Market Cap
- DBL 280.4M
- OLMA 299.7M
- IPO Year
- DBL N/A
- OLMA 2020
- Fundamental
- Price
- DBL $15.46
- OLMA $4.20
- Analyst Decision
- DBL
- OLMA Strong Buy
- Analyst Count
- DBL 0
- OLMA 4
- Target Price
- DBL N/A
- OLMA $24.50
- AVG Volume (30 Days)
- DBL 61.0K
- OLMA 868.7K
- Earning Date
- DBL 01-01-0001
- OLMA 08-05-2025
- Dividend Yield
- DBL 8.67%
- OLMA N/A
- EPS Growth
- DBL N/A
- OLMA N/A
- EPS
- DBL N/A
- OLMA N/A
- Revenue
- DBL N/A
- OLMA N/A
- Revenue This Year
- DBL N/A
- OLMA N/A
- Revenue Next Year
- DBL N/A
- OLMA N/A
- P/E Ratio
- DBL N/A
- OLMA N/A
- Revenue Growth
- DBL N/A
- OLMA N/A
- 52 Week Low
- DBL $13.75
- OLMA $2.86
- 52 Week High
- DBL $15.70
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- DBL 44.72
- OLMA 43.60
- Support Level
- DBL $15.51
- OLMA $3.90
- Resistance Level
- DBL $15.78
- OLMA $4.29
- Average True Range (ATR)
- DBL 0.13
- OLMA 0.36
- MACD
- DBL -0.01
- OLMA -0.03
- Stochastic Oscillator
- DBL 25.56
- OLMA 19.18
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.